File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer

TitleA phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer
Authors
KeywordsBevacizumab
Capecitabine
Metastatic colorectal cancer
Oxaliplatin
Phase II
Issue Date2011
Citation
Clinical Colorectal Cancer, 2011, v. 10 n. 3, p. 210-216 How to Cite?
AbstractBackground: This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer. Patients and Methods: Nineteen patients with previously untreated advanced colorectal cancer received capecitabine at 1000 mg/m 2 twice a day on days 1-5 and days 8-12 of a 14-day cycle, and OHP at 85 mg/m 2 and bevacizumab at 10 mg/kg every 2 weeks. Because of unacceptable toxicities, the capecitabine dose was reduced to 850 mg/m 2. Thirty-one additional patients were treated at the lower capecitabine dose. Treatment continued until disease progression, persistent intolerable toxicity, or physician and/or patient discretion. Results: Overall, toxicities were better managed and tolerated at the 850 mg/-m 2 capecitabine dose. The most common treatment-related grade < 3 toxicities were diarrhea and sensory neuropathy. In the first 19 subjects, the response rate was 63% (95% confidence interval [CI], 38%-84%) and 5 patients had stable disease; median progression-free survival (PFS) was 10.1 months (95% CI, 5.7-19.5 months). In the subsequent 31 patients, the response was 42% (95% CI, 25%-61%); 11 patients had stable disease and median PFS was 10.4 months (95% CI, 6.9-15.4); median overall survival was 24.8 months (95% CI, 12.9-39.7). Conclusions: This novel regimen of capecitabine at 850 mg/m 2 twice a day on days 1-5 and days 8-12 and OHP at 85 mg/m 2and bevacizumab at 10 mg/kg every 14 days is clinically active in advanced colorectal cancer. The toxicity profile of this regimen is consistent with the standard every-3-week dosing schedule. © 2011 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/194321
ISSN
2019 Impact Factor: 3.245
2015 SCImago Journal Rankings: 1.382
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, NS-
dc.contributor.authorFernando, NH-
dc.contributor.authorBendell, JC-
dc.contributor.authorMorse, MA-
dc.contributor.authorBlobe, GC-
dc.contributor.authorHoneycutt, W-
dc.contributor.authorPang, H-
dc.contributor.authorHurwitz, HI-
dc.date.accessioned2014-01-30T03:32:27Z-
dc.date.available2014-01-30T03:32:27Z-
dc.date.issued2011-
dc.identifier.citationClinical Colorectal Cancer, 2011, v. 10 n. 3, p. 210-216-
dc.identifier.issn1533-0028-
dc.identifier.urihttp://hdl.handle.net/10722/194321-
dc.description.abstractBackground: This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer. Patients and Methods: Nineteen patients with previously untreated advanced colorectal cancer received capecitabine at 1000 mg/m 2 twice a day on days 1-5 and days 8-12 of a 14-day cycle, and OHP at 85 mg/m 2 and bevacizumab at 10 mg/kg every 2 weeks. Because of unacceptable toxicities, the capecitabine dose was reduced to 850 mg/m 2. Thirty-one additional patients were treated at the lower capecitabine dose. Treatment continued until disease progression, persistent intolerable toxicity, or physician and/or patient discretion. Results: Overall, toxicities were better managed and tolerated at the 850 mg/-m 2 capecitabine dose. The most common treatment-related grade < 3 toxicities were diarrhea and sensory neuropathy. In the first 19 subjects, the response rate was 63% (95% confidence interval [CI], 38%-84%) and 5 patients had stable disease; median progression-free survival (PFS) was 10.1 months (95% CI, 5.7-19.5 months). In the subsequent 31 patients, the response was 42% (95% CI, 25%-61%); 11 patients had stable disease and median PFS was 10.4 months (95% CI, 6.9-15.4); median overall survival was 24.8 months (95% CI, 12.9-39.7). Conclusions: This novel regimen of capecitabine at 850 mg/m 2 twice a day on days 1-5 and days 8-12 and OHP at 85 mg/m 2and bevacizumab at 10 mg/kg every 14 days is clinically active in advanced colorectal cancer. The toxicity profile of this regimen is consistent with the standard every-3-week dosing schedule. © 2011 Elsevier Inc. All rights reserved.-
dc.languageeng-
dc.relation.ispartofClinical Colorectal Cancer-
dc.subjectBevacizumab-
dc.subjectCapecitabine-
dc.subjectMetastatic colorectal cancer-
dc.subjectOxaliplatin-
dc.subjectPhase II-
dc.titleA phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.clcc.2011.03.018-
dc.identifier.pmid21855046-
dc.identifier.scopuseid_2-s2.0-80052456693-
dc.identifier.volume10-
dc.identifier.issue3-
dc.identifier.spage210-
dc.identifier.epage216-
dc.identifier.isiWOS:000294157100012-
dc.identifier.issnl1533-0028-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats